In-depth Protein Analysis in FFPE tissue

Discover and Validate

Mine archival tissue collections for differentially expressed protein biomarkers. EPI's patented technologies work together to enable protein biomarker discovery and validation in the standard form of patient tissue.

* Companion diagnostics * Prognostic biomarkers * Drug targets

Measure

Quantify proteins in tissue. EPI's technology has great potential in drug development, clinical trials and personalized medicine. Measuring protein expression in standard formalin-fixed tissue samples can provide diagnostic and prognostic information to guide treatment decisions.

* Absolute quantitation * Multiplexed * Proteins and pathways

Enabling Technology Platform

Our research and product development is based on two proprietary technologies; tissue dissection using our DIRECTOR laser microdissection slides, and the ability to solubilize FFPE tissue using the patented Liquid Tissue MS Protein Prep protocol so the sample can be analyzed using a range of different mass spectroscopy applications.

Liquid Tissue® and DIRECTOR® are registered trademarks of Expression Pathology Inc.

Liquid Tissue technology is protected by U.S. Patent 7,473,532 and patents pending and foreign equivalents thereof. DIRECTOR technology is protected by U.S. Patents 7,294,367 and 7,381,440 and foreign equivalents thereof.

. Our Terms and Conditions apply. The Liquid Tissue® MS is sold under a limited license with commercial use restrictions. For further details please contact us.

Expression Pathology Inc. is a leader in tissue proteomics.

Using our tissue analysis platform we are developing proprietary new cancer tests in tissue. The tests will provide information to guide treatment decisions – the presence of protein drug targets, or which biological pathways are activated in tumors to aid prognosis and drug selection.

Download references and application notes here.

news sidebar

News & Events

Biomarker World Congress (BMW), Philadelphia, May 27-29. Don't miss our breakfast seminar, In-depth protein analysis in FFPE tissue, on Thursday, May 28.
American Society of Mass Spectrometry (ASMS), Philadelphia, May 31-June 4.
Expression Pathology raises $6.5 Million to develop personalized medicine assays for protein biomarkers in FFPE Tissue. April 20, 2009 (press release)
Expression Pathology Inc. announced today the move of its headquarters and R&D to a new location. March 27, 2009.
American Association of Cancer Research (AACR) annual meeting, Denver, April 19-22. Meet us at booth 1468.
New Publication: Proteomic Analysis of Paraffin Embedded Archival Melanoma Tissue Reveals Biomarkers Associated with Metastasis. PLoS ONE 4(2): e4430. doi:10.1371/journal.pone.0004430 Feb. 17, 2009
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology, Jan. 6, 2009 (press release)
Expression Pathology and NextGen Sciences develop Liquid Tissue® MRM assay for measurement of Her2 in FFPE tissue, Dec. 17, 2008 (application note)
Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research, Sept. 26, 2008 Tissue Proteomics Technology to Identify Protein Biomarkers of Metastasis (press release)